Due to arguments showing that angiogenesis could be involved in progression of metastatic
thyroid carcinoma and to objective response during previous studies with sunitinib (an
angiogenic oncology drug also known as Sutent), this study, THYSU, is justified to evaluate
the efficacy of sunitinib in metastatic thyroid carcinoma. Furthermore, the standard
treatment of metastatic thyroid carcinoma when a general treatment is to be prescribed is
limited to radioiodine. When radioiodine becomes ineffective, there is no standard treatment
despite some use of chemotherapy.
The objective of the trial is to determine the objective tumor response rate (efficacy) in
patients with locally advanced or metastatic anaplastic, differentiated or medullary thyroid
carcinoma treated with sunitinib; a secondary objective is to evaluate the safety of
sunitinib in these patients.
The THYSU trial is a phase II, French multi-center study. This trial's plan is to enroll 75
patients with locally advanced or metastatic anaplastic, differentiated or medullar thyroid
carcinoma.